CN Patent

CN120390655A — 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途

Assigned to Zhejiang Teruisi Pharmaceutical Inc · Expires 2025-07-29 · 1y expired

What this patent protects

抗CD20抗体药物偶联物在制备治疗NHL的药物中的用途，所述药物在治疗接受至少两次标准治疗后的复发或难治NHL上具有良好的临床疗效及安全性。

USPTO Abstract

抗CD20抗体药物偶联物在制备治疗NHL的药物中的用途，所述药物在治疗接受至少两次标准治疗后的复发或难治NHL上具有良好的临床疗效及安全性。

Drugs covered by this patent

Patent Metadata

Patent number
CN120390655A
Jurisdiction
CN
Classification
—
Expires
2025-07-29
Drug substance claim
No
Drug product claim
No
Assignee
Zhejiang Teruisi Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.